Enveric Biosciences (ENVB) Non-Current Debt (2015 - 2020)

Enveric Biosciences (ENVB) posted Non-Current Debt of $146976.0 for Q3 2020, down 1.95% sequentially from $149900.0 in Q2 2020.

Enveric Biosciences (ENVB) Non-Current Debt (2015 - 2020) Analysis & Trends

Enveric Biosciences has reported Non-Current Debt for 5 years, with the latest figure at $146976.0 in Q3 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $146976.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $146976.0 (changed N/A YoY) and the FY2017 annual result came in at $1.1 million, down 26.4% from the prior year.
Non-Current Debt slipped to $146976.0 in Q3 2020 per ENVB's latest filing, from $149900.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $5.5 million in Q2 2016 and troughed at $1698.0 in Q3 2018.
A 4-year average of $1.3 million and a median of $1.0 million in 2018 frame the typical range for Non-Current Debt.
The sharpest annual moves came in 2016 and 2018: Non-Current Debt surged 526.67% in 2016, then sank 99.89% in 2018.
Over 4 years, Non-Current Debt stood at $1.5 million in 2016, then decreased by 26.4% to $1.1 million in 2017, then sank by 99.85% to $1698.0 in 2018, then soared by 8555.83% to $146976.0 in 2020.
According to Business Quant data, Non-Current Debt over the past three periods registered $146976.0, $149900.0, and $1698.0 for Q3 2020, Q2 2020, and Q3 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	-
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	8.96 Bn
10	Enveric Biosciences	5.58 Mn	-2.71 Mn	-	-

Download Data